A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomasPresented, in part, at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 31June 3, 2003 (abstract 3291).

MLA

Robert G. Maki, et al. “A Multicenter Phase II Study of Bortezomib in Recurrent or Metastatic SarcomasPresented, in Part, at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 31June 3, 2003 (Abstract 3291).” Cancer (0008543X), vol. 103, no. 7, Mar. 2005, pp. 1431–38. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=18567702&authtype=sso&custid=ns315887.

APA

Robert G. Maki, Andrew S. Kraft, Kelly Scheu, Jennifer Yamada, Scott Wadler, Cristina R. Antonescu, John J. Wright, & Gary K. Schwartz. (2005). A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomasPresented, in part, at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 31June 3, 2003 (abstract 3291). Cancer (0008543X), 103(7), 1431–1438.

Chicago

Robert G. Maki, Andrew S. Kraft, Kelly Scheu, Jennifer Yamada, Scott Wadler, Cristina R. Antonescu, John J. Wright, and Gary K. Schwartz. 2005. “A Multicenter Phase II Study of Bortezomib in Recurrent or Metastatic SarcomasPresented, in Part, at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 31June 3, 2003 (Abstract 3291).” Cancer (0008543X) 103 (7): 1431–38. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=18567702&authtype=sso&custid=ns315887.